Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies

Biotechnology and Bioengineering

Volumn 96, Issue 2, 2007, Pages 294-306

  Hartman, Taymar E ^a   Sar, Nalin ^a   Genereux, Kimberly ^a   Barritt, Diana S ^a   He, Yimin ^a   Burky, John E ^a   Wesson, Mark C ^a   Tso, J Yun ^a   Tsurushita, Naoya ^a   Zhou, Weichang ^a   Sauer, Paul W ^a  

^a PDL BioPharma Inc   (United States)

Author keywords

Cholesterol free; gpt; Humanized antibody; NS0 host cell line; Protein free; Stable cell lines

Indexed keywords

CELL CULTURE; CELLS; CHOLESTEROL; ESCHERICHIA COLI; GENES;

HUMANIZED ANTIBODIES; NS0 HOST CELL LINE; STABLE CELL LINES;

ANTIBODIES;

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; RECOMBINANT ANTIBODY; XANTHINE; CHOLESTEROL; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BIOREACTOR DESIGN; CELL LINE; CHOLESTEROL INTAKE; CULTURE MEDIUM; ELECTROPORATION; ESCHERICHIA COLI; FED BATCH CULTURE; GENETIC ANALYSIS; GENETIC TRANSFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; QUALITATIVE ANALYSIS; ANIMAL; BIOREACTOR; BIOSYNTHESIS; CULTURE TECHNIQUE; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE;

ESCHERICHIA COLI;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CHOLESTEROL; HUMANS; MICE; RECOMBINANT PROTEINS;

EID: 33846914842     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21099     Document Type: Article

References (44)

1. Andersen DC, Krummen L. 2002. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13(2):117-123.
2. Balland A, Faure T, Carvallo D, Cordier P, Ulrich P, Fournet B, de la Salle H, Lecocq JP. 1988. Characterisation of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector. Eur J Biochem 172(3):565-572.
3. Barnes LM. 2000. Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology 32(2):109-123.
4. Barnes LM, Bentley CM, Dickson AJ. 2004. Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnol Bioeng 85(2):115-121.
5. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. 1992. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 10(2):169-175.
6. Bendig MM. 1988. The production of foreign proteins in mammalian cells. Genet Eng (7):91-127.
7. Birch JR, Boraston RC, Metcalfe H, Brown ME, Bebbington CR, Field RP. 1994. Selecting and designing cell lines for improved physiological characteristics. Cytotechnology 15(1-3):11-16.
8. Borth N, Zeyda M, Kunert R, Katinger H. 2000. Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. Biotechnol Bioeng 71(4):266-273.
9. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41(2):521-530.
10. Burky JE, Wesson MC, Young A, Farnsworth F, Dionne B, Zhu Y, Hartman TE, Qu L, Zhou W, Sauer PW. 2006. Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol Bioeng 96:281-293.
11. Cazzola F, Saggin L, Callegaro L. 1992. Production of novel monoclonal antibodies against rabbit platelet factor four. Hybridoma 11(1):61-69.
12. Chadd HE, Chamow SM. 2001. Therapeutic antibody expression technology. Curr Opin Biotechnol 12(2):188-194.
13. Cockett MI, Bebbington CR, Yarranton GT. 1990. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (NY) 8(7):662-667.
14. Cole MS, Anasetti C, Tso JY. 1997. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 159(7):3613-3621.
15. Galfre G, Milstein C. 1981. Preparation of monoclonal antibodies: Strategies and procedures. Methods Enzymol 73(Pt B):3-46.
16. Gorfien S, Paul B, Walowitz J, Keem R, Biddle W, Jayme D. 2000. Growth of NS0 cells in protein-free, chemically defined medium. Biotechnol Prog 16(5):682-687.
17. Gramer MJ, Maas J. 2003. Optimal NS0 cell growth in a hollow fiber bioreactor requires increased serum concentration or a cholesterol supplement on the cell side of the fiber. Biotechnol Prog 19(6):1762-1766.
18. Holmes P, Al-Rubeai M. 1999. Improved cell line development by a high throughput affinity capture surface display technique to select for high secretors. J Immunol Methods 230(1-2):141-147.
19. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176(5):1215-1224.
20. Kawamoto T, Sato JD, Le A, McClure DB, Sato GH. 1983. Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas. Anal Biochem 130(2):445-453.
21. Kearns B. 2003. NS0 batch cell culture process characterization: A case study. BioProcess J 2(1):52-57.
22. Keen MJ. 1995. Adaptation of cholesterol-requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium. Cytotechnology 17:203-211.
23. Kim SJ, Kim NS, Ryu CJ, Hong HJ, Lee GM. 1998. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 58(1):73-84.
24. Lin L, Gillies SD, Schlom J, Pestka S. 1998. Construction of phosphorylatable monoclonal antibody CC49 with a casein kinase II recognition site. Anticancer Res 18(6A):3971-3978.
25. Lupker JH, Roskam WG, Miloux B, Liauzun P, Yaniv M, Jouannau J. 1983. Abundant excretion of human growth hormone by recombinant-plasmid-transformed monkey kidney cells. Gene 24(2-3):281-287.
26. Lyaku JR, Sinclair JA, Nettleton PF, Marsden HS. 1992. Production and characterization of monoclonal antibodies to cervine herpesvirus-1. Vet Microbiol 32(3-4):229-239.
27. Merten OW. 1999. Safety issues of animal products used in serum-free media. Dev Biol Stand 99:167-180.
28. Mulligan RC, Berg P. 1981. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyl-transferase. Proc Natl Acad Sci USA 78(4):2072-2076.
29. Novak M, Borecky L, Kontsekova E, Kontsek P, Novakova M. 1986. Preparation and characterization of hybridomas producing monoclonal antibodies against human alpha interferon. Acta Virol 30(3):228-233.
30. Physician's Desk Reference. 2005. 59th edition. Montvale, NJ: Thomson PDR. p 3344-3347.
31. Richards CM, Aucken HA, Tucker EM, Hannant D, Mumford JA, Powell JR. 1992. The production of equine monoclonal immunoglobulins by horse-mouse heterohybridomas. Vet Immunol Immunopathol 33(1-2):129-143.
32. Richardson KK, Fostel J, Skopek TR. 1983. Nucleotide sequence of the xanthine guanine phosphoribosyl transferase gene of E. coli. Nucleic Acids Res 11(24):8809-8816.
33. Ringold G, Dieckmann B, Lee F. 1981. Co-expression and amplification of dihydrofolate reductase cDNA and the Escherichia coli XGPRT gene in Chinese hamster ovary cells. J Mol Appl Genet 1(3):165-175.
34. Sambrook J. 2001. Molecular Cloning: A Laboratory Manual, 3rd edn New York: Cold Spring Harbor Laboratory Press.
35. Sato JD, Cao HT, Kayada Y, Cabot MC, Sato GH, Okamoto T, Welsh CJ. 1988. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium. In Vitro Cell Dev Biol 24(12):1223-1228.
36. Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L. 2000. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol Bioeng 67(5):585-597.
37. Seth G, McIvor RS, Hu WS. 2006a. 17Beta-hydroxysteroid dehydrogenase type 7 (Hsd17b7) reverts cholesterol auxotrophy in NS0 cells. J Biotechnol 121(2):241-252.
38. Seth G, Ozturk M, Hu WS. 2006b. Reverting cholesterol auxotrophy of NS0 cells by altering epigenetic gene silencing. Biotechnol Bioeng 93(4):820-827.
39. Walowitz JL, Fike RM, Jayme DW. 2003. Efficient lipid delivery to hybridoma culture by use of cyclodextrin in a novel granulated dry-form medium technology. Biotechnol Prog 19(1):64-68.
40. Wang X, Yu M, Wang J, Wu S, Hu Y, Hou Y. 1989. Expression of human interferon beta gene controlled by SV40 late promoter in mouse myeloma SP2/0 cells. Yi Chuan Xue Bao 16(5):399-403.
41. Weidle UH, Buckel P, Wienberg J. 1988. Amplified expression constructs for human tissue-type plasminogen activator in Chinese hamster ovary cells: Instability in the absence of selective pressure. Gene 66(2):193-203.
42. Werge TM, Bradbury A, Di Luzio A, Cattaneo A. 1992. A recombinant cell line expressing a form of the Y13-259 anti-p21ras antibody which binds protein A and may be produced as ascites. Oncogene 7(5):1033-1035.
43. Whitford W. 2003. NS0 Serum-Free Culture and Applications. BioProcess Int 1(12):36-47.
44. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393-1398.